Edwards Lifesciences Corp. said it projects 2021 global sales of $4.9 billion to $5.3 billion, for underlying growth in the mid-teens.
The FactSet consensus is for 2021 sales of $5.1 billion.
Edwards guided for 2021 adjusted earnings per share of $2.00 to $2.20. The FactSet consensus is $2.21.
The company projected 2021 Transcatheter Aortic Valve Replacement sales of $3.2 billion to $3.6 billion, for underlying growth 15% to 20%.
Shares were up about 3% to $87.35 in morning trading.
The provider of medical products for heart disease and critical care monitoring said it is discussing its strategy for longer-term growth, providing an update on its technology pipeline and giving financial guidance during its annual investor conference Thursday.
"Although we expect the pandemic to have a continuing impact on the global healthcare system, we are very optimistic about 2021 and we anticipate returning to strong, double-digit top-line growth," said Chief Executive Michael A. Mussallem.
Edwards said it continues to believe the global TAVR opportunity will reach more than $7 billion by 2024, with continuing growth thereafter, fueled by therapy expansion, technology advances and geographic expansion.
The company said it expects the current $1.8 billion surgical structural heart opportunity to grow mid-single digits through 2026 driven by global cardiac procedure growth.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.